GEN Exclusives

More »

GEN News Highlights

More »
Mar 20, 2007

Adventrx Awards Manufacturing Contract to Pharmatek Labs

  • Adventrx Pharmaceuticals entered into an agreement with Pharmatek Laboratories for the manufacturing of ANX-201 (Thiovir) capsules for clinical studies.

    “Pharmatek is an experienced contract manufacturer and we are confident in their ability to produce reliable cGMP material for our clinical trials,” says Michele Yelmene, vp of regulatory affairs. “The drug supply they generate under this contract is expected to provide the company with inventory for our Phase I/II study in HIV, which we anticipate initiating later this year.”

    ANX-201 is a member of a new class of reverse transcriptase inhibitors designed for oral delivery as a component of AZT-based highly active antiretroviral therapy. The product is a pyrophosphate analog that delivers both thiophosphonoformate and phosphonoformate (PFA, foscarnet).


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Disclosing Clinical Trial Data

Do you believe that conducting performance audits for new drugs will incentivize pharma firms to become more transparent?

More »